REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 26.50
Bid: 26.00
Ask: 27.00
Change: 0.00 (0.00%)
Spread: 1.00 (3.846%)
Open: 26.50
High: 26.50
Low: 26.50
Prev. Close: 26.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Renalytix PLC - Replacement

15 Mar 2024 10:23

RNS Number : 0590H
Polar Capital Holdings PLC
15 March 2024

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

Amendment - this form replaces RNS number 7712G, published at 18:14 on 13/03/2024. Changes have been made to Sections 1,2(a), 2(b) and 3(d). Amendments are marked with an asterisk (*). The full amended text is shown below.

1. KEY INFORMATION

(a) Full name of discloser:

Polar Capital LLP, the Investment Manager, disclosing on behalf of:

Polar Capital Funds PLC - Biotechnology Fund

Polar Capital Funds PLC - Healthcare Discovery Fund

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

RENALYTIX PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

12/03/2024*

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

0.025 GBp Ordinary Shares

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

4,115,671*

4.11*

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

4,115,671*

4.11*

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:

0.025 GBp Ordinary Shares*

Details, including nature of the rights concerned and relevant percentages:

Agreed to subscribe to 9,750,390 new shares at a price of 0.2 GBP in Renalytix plc placing on 12 March 2024.*

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)*

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

15.03.2024

Contact name:

Ellie Martin

Telephone number*:

+44 20 3862 2578

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RETZZGMFGKMGDZM
Date   Source Headline
22nd Apr 20212:00 pmRNSPrice Monitoring Extension
22nd Apr 202111:05 amRNSSecond Price Monitoring Extn
22nd Apr 202111:00 amRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNS10-year US Government contract award
20th Apr 20217:00 amRNSPositive clinical outcome data for KidneyIntelX
19th Apr 20217:00 amRNSDirector/PDMR Shareholding
14th Apr 20217:00 amRNSExclusive option agreement
8th Apr 20217:00 amRNSClinical Utility Study
6th Apr 20217:00 amRNSClinical findings published in Diabetologia
15th Mar 20217:00 amRNSUpdate on Finalization of MCIT Rule
4th Mar 20216:00 pmRNSIssue of shares, PDMR Dealing and TVR
2nd Mar 20217:02 amRNSFinancial Results for Second Quarter of FY 2021
2nd Mar 20217:00 amRNSHalf-year Report
24th Feb 20217:00 amRNSUniversity of Utah Kidney Health Partnership
23rd Feb 20217:00 amRNSNotice of Results
4th Feb 20217:00 amRNSASN & Renalytix to Co-Host Capital Markets Day
13th Jan 20214:35 pmRNSPrice Monitoring Extension
13th Jan 20217:00 amRNSFinalization of MCIT rule for coverage pathway
5th Jan 20214:41 pmRNSSecond Price Monitoring Extn
5th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSPartnership Between RenalytixAI and DaVita
4th Jan 20217:00 amRNSRENX to present at 39th JP Morgan Healthcare Conf.
7th Dec 20203:45 pmRNSResult of AGM
2nd Dec 20201:08 pmRNSPartnership with National Kidney Foundation
26th Nov 20207:01 amRNSHolding(s) in Company
26th Nov 20207:00 amRNSSale of shares in Renalytix AI plc
25th Nov 20204:41 pmRNSSecond Price Monitoring Extn
25th Nov 20204:35 pmRNSPrice Monitoring Extension
25th Nov 20207:00 amRNSFinancial Results for First Quarter of FY 2021
13th Nov 20207:00 amRNSStifel 2020 Healthcare Conference
6th Nov 20207:00 amRNSChange of Adviser
2nd Nov 20203:30 pmRNSPosting of Annual Report & Accounts &Notice of AGM
28th Oct 20202:15 pmRNSRe-issued: EKF marketing & distribution agreement
27th Oct 20207:00 amRNSFull Year Report
20th Oct 202012:00 pmRNSSchedule One - Verici Dx PLC
16th Oct 20207:00 amRNSNotice of Results
13th Oct 20203:32 pmRNSVerici Dx - Intention to admit to trading on AIM
22nd Sep 20207:00 amRNSCalifornia Commercial Lab Certification Recieved
18th Sep 20207:00 amRNSKidneyIntelX clinical testing launch
2nd Sep 20207:00 amRNSGrant of Purchase Rights and Verici update
26th Aug 20207:00 amRNSSubmission seeking FDA Clearance of KidneyIntelX
21st Aug 20208:00 amRNSRenalytixAI to Collaborate with AstraZeneca
3rd Aug 20207:00 amRNSKidneyIntelX in Multi-Center Study
31st Jul 20204:31 pmRNSTotal Voting Rights
27th Jul 20207:00 amRNSOver allotment option exercise
21st Jul 20205:30 pmRNSClosing of Global Offering and resulting TVR
17th Jul 20207:00 amRNSPricing of Global Offering
13th Jul 202012:01 pmRNSLaunch of Global Offering and application to list
13th Jul 202011:45 amRNSResult of General Meeting
8th Jul 20207:01 amRNSApproval of distribution of shares in Verici Dx

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.